ecancermedicalscience

Short Communication

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis, such as the COVID-19 pandemic

27 Apr 2020
Covadonga Marti, José I Sánchez-Méndez

The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or postponing their attendance at clinics, as well as avoiding surgeries. In this scenario, neoadjuvant endocrine treatment could be an appropriate alternative treatment for hormone receptor positive breast cancer (luminal-like tumours) in order to minimise hospital admissions and to delay elective surgeries. Accordingly, we present a simple protocol that can be applied to most cases of luminal-like breast cancer and is appropriate for the majority of secondary or tertiary medical centres, or even primary care.

Related Articles

Astghik Voskanyan, Lusine Harutyunyan, Arusyak Ivanyan, Alisa Movsisyan, Nerses Ghahramanyan, Lusine Sahakyan, Shushan Hovsepyan, Samvel Danielyan, Hayk Grigoryan, Gevorg Tamamyan
Adu Bukola Gift, Michael Joseph Otorkpa, Oluwatobi O. Olayode, Ebubechukwu David Joseph, Ademola Abdulhakeem, Efuetlateh John Paul Nchonganyi, Feziechi Chikelundu Anele, Akolade Akeem Habib, Fodop Samuel Ghislain Junior, Oluwanifemi O. Akintoye, Omoregbee Benjamin
João Felipe Lima Feldmann, João Henrique Lima Feldmann, Cassio Murilo Hidalgo-Filho, Amanda Acioli de Almeida Robatto, Breno Jeha Araújo, Publio Cesar Cavalcante Viana, Gilberto de Castro Junior
Naciri Meryem, Aouzah Fatima Ezzahra, El Ghanmi Adil, Ghazi Bouchra Fichtali Karima Sqalli Houssaini Mohammed, Kouhen Fadila